CDX2-positive or CDX2-negative status were equally represented in tumours with wild-type (N = 178, 51.4%) or mutated (N = 168, 48.6%) KRAS or NRAS. The BRAF p.V600E variant was more frequent among CDX2-negative tumours, detected in six (40%) of them as compared to nine (60%) CDX2-positive samples (Table 2). Here, KRAS is linked to neoplasm.